1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Ionis Could Be A Factor In MASH With Positive Phase II Data

 
• By Joseph Haas

Ionis’s DGAT2 inhibitor showed potential to improve disease activity score and resolve metabolic-associated steatohepatitis in a Phase II study, but analysts point to fibrosis-reduction data as competitively intriguing.

Business, Technology, Internet and network concept. Young businessman working on a virtual screen of the future and sees the inscription: Clinical trial
Ionis's Phase II data may put its MASH candidate in the thick of the R&D race • Source: Shutterstock

As the industry awaits the potential first approval of a metabolic-associated steatohepatitis (MASH) drug on 14 March, Ionis Pharmaceuticals, Inc. may have worked its way into the race to follow Madrigal Pharmaceuticals, Inc.’s THRβ agonist resmetirom into the market, unveiling top-line Phase II data on 13 March for its antisense DGAT2 inhibitor ION224 that met statistical significance for biopsy-demonstrated improvement in disease score along with a secondary endpoint of MASH resolution.

Key Takeaways

  • Ionis hits primary and secondary endpoints in a Phase II trial of its antisense candidate for MASH.

In the 51-week study, two doses of ION224 – 120mg and 90 mg, each dosed subcutaneously once a month –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

More from R&D

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

 
• By Alaric DeArment

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.